Prevention of migraine by supraorbital transcutaneous neurostimulation using the Cefaly® device (PREMICE): a multi-centre, randomized, sham-controlled trial by J Schoenen et al.
POSTER PRESENTATION Open Access
Prevention of migraine by supraorbital
transcutaneous neurostimulation using the
Cefaly®device (PREMICE): a multi-centre,
randomized, sham-controlled trial
J Schoenen1*, B Vandersmissen2, S Jeangette2, L Herroelen2, M Vandenheede2, P Gerard1, D Magis1
From The European Headache and Migraine Trust International Congress
London, UK. 20-23 September 2012
Introduction
Subjects who have frequent migraine attacks (≥ 2 / month)
are in need of a preventive anti-migraine treatment. Avail-
able preventive drugs have incomplete efficacy and/or
unpleasant side effects.
Purpose
Supraorbital transcutaneous neurostimulation (STNS)
has shown encouraging results for migraine prevention
in pilot studies and has no side effects [1-3]. We assessed
efficacy and safety of STNS in migraine prophylaxis with
the Cefaly® device in a multicentre, double-blind, rando-
mized, sham-controlled trial.
Methods
Five Belgian tertiary headache clinics participated to the
study. After a 1-month run-in, patients with ≥ 2 migraine
attacks/month were randomized to verum or sham stimu-
lation, and applied the Cefaly® device daily for 20 minutes
during 3 months. Primary outcome measures were change
in monthly migraine days and 50% responder rate, i.e. the
percentage of subjects having a ≥ 50% reduction of
monthly migraine days. Patients and enrolling neurologists
were blinded from the randomization.
Results
Sixty-seven patients were randomized and included in the
intention-to-treat analysis. Between run-in and 3rd month
of treatment the mean number of migraine days decreased
significantly in the verum (4.88 vs 6.94; p=0.023), but not
in the sham group (6.22 vs 6.54; p=0.608). The 50%
responder rate was significantly greater (p=0.023) in the
verum (38.1%) than in the sham group (12.1 %). Monthly
migraine attacks (p=0.044), monthly headache days
(p=0.041) and monthly acute anti-migraine drug intake
(p=0.007) were also significantly reduced in the verum but
not in the sham group. There were no adverse events in
either group.
Conclusions
STNS with the Cefaly® device is effective as a preventive
therapy for migraine. The therapeutic gain (26%) is within
the range of those reported for other preventive drug and
non-drug anti-migraine treatments [4,5], and the safety
profile is excellent.
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